Condition

Cardiac Toxicity

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 19 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials19

Recruiting4

Common interventions25

Lead sponsors shown15

Clinical trials

19 shown

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)NCT05465031 · 2024-04-17

The STOP-MED CTRCD TrialNCT06183437 · 2024-03-04

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 TargetedNCT05559164 · 2022-09-19

COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)NCT05258448 · 2015-08-01

Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High AltitudeNCT05063643 · 2021-10-01

Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.NCT06277388 · 2021-06-05

ACTIVE_NOT_RECRUITING

Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer RadiotherapyNCT04867564 · 2021-05-01

Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer PatientsNCT04962425 · 2021-01-08

The CAROLE (CArdiac Related Oncologic Late Effects) StudyNCT03235427 · 2017-06-27

BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT StudyNCT02605512 · 2015-10-01

MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity AddendumNCT01719562 · 2013-01-01

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving TrastuzumabNCT01009918 · 2010-03-01

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast CancerNCT01093235 · 2009-04-01

Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and TrastuzumabNCT00875238 · 2008-06-01

CADY Study ICORG 08-01NCT00968682 · 2008-04-01

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By SurgeryNCT00436566 · 2007-03-16

Novel Surrogate Markers as Predictors of Radiation Toxicity in Breast Cancer Patients Undergoing Helical Tomotherapy Compared to Standard Radiation TherapyNCT00563407 · 2006-07-01

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast CancerNCT00016276 · 2001-05-01

SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical TrialNCT00002900 · 1997-02-01

Common interventions

Leading sponsors

Affiliated Hospital of Qinghai University1 AHS Cancer Control Alberta1 Cambridge University Hospitals NHS Foundation Trust1 Cancer Trials Ireland1 Dinesh Thavendiranathan1 Mayo Clinic1 Military Institute od Medicine National Research Institute1 National Cancer Institute (NCI)1 Northwell Health1 Odense University Hospital1 Peking University Third Hospital1 Rutgers, The State University of New Jersey1 Silesian Centre for Heart Diseases1 Sophie JACOB1 Sun Yat-sen University1

Trial status mix

COMPLETED8

RECRUITING4

UNKNOWN4

TERMINATED2

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE23

NA2

PHASE32

PHASE42

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.